FDA panel unanimously recommends approval of Vistide for CMV retinitis. Food and Drug Administration.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D007668:Kidney / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents